Floseal Hemostatic Matrix may improve blood-loss control in TKA
Use of Floseal Hemostatic Matrix in total knee arthroplasty safely provided improved control of blood loss and reduced the predicted probability of postoperative blood transfusion, according to study results.
One hundred and fifty-seven patients undergoing total knee arthroplasty (TKA) received either 5 mL or 10 mL Floseal Hemostatic Matrix (Baxter Healthcare Corporation) during surgery and warfarin as thromboprophylaxis starting the day after surgery. Researcher John H. Velyvis, MD, extracted data via hospital chart review from 100 consecutive patients who underwent TKA but did not receive Floseal for the control group.
Results showed significantly lower postoperative drainage in the 10 mL group vs. the 5 mL and in both the 10 mL and 5 mL groups vs. the control group. Although Velyvis found no significant difference in the predicted probability of transfusion between the 5 mL and control group, there was a lower predicted probability of transfusion in the 10 mL group vs. the control group.
Application of Floseal either before or after tourniquet release had a similarly significant effect on drainage volume and predicted probability of blood transfusion in the 10 mL group, according to study results. Velyvis reported observing differences in outcomes by type of anesthesia used, and no adverse events related to Floseal use occurred. – by Casey Tingle
Disclosure: Velyvis is a paid consultant for Baxter Healthcare Corporation.